Short Reads or Long Reads: How to Pick the Right Sequencing Platform for Your Study

There is no single best next-generation sequencing platform—only the best match for a defined experiment. The central trade-off in the field is straightforward: short-read instruments such as the Illumina NovaSeq 6000 and MGI DNBSEQ-T7 deliver high accuracy and low cost per base, while long-read systems from PacBio and Oxford Nanopore stretch reads from hundreds of bases to tens of thousands, unlocking regions short reads cannot resolve. Here is how the evidence stacks up when choosing between them.

Understanding Next-Generation Sequencing Technologies

Next-generation sequencing has reshaped genomics by enabling comprehensive genome sequencing alongside transcriptomics, epigenomics, metagenomics and other omics studies, according to a review of current trends in the technology. Its high-throughput capacity and cost-effectiveness have made it a fundamental tool across disciplines ranging from basic biology to clinical diagnostics.

The platforms divide into two broad families. Short-read sequencers produce reads of roughly 600–700 bases at most; long-read, third-generation platforms can generate reads up to 25–30 kilobases, a review of NGS technology reports. That order-of-magnitude difference in read length is not a marginal specification—it determines which questions each instrument can actually answer.

A further distinction sits in library preparation. Long-read workflows can be PCR-free, which removes amplification bias. As the review puts it, "the base modification such as DNA methylation can be easily detected by long-read sequencing"—a capability PCR-amplified short-read workflows do not offer as directly. The same review notes that newer high-throughput platforms have significantly reduced error rates and improved long-read accuracy, narrowing what was once the technology's main weakness.

Short-Read Sequencing: Illumina and MGI

The workhorses of this category are the Illumina NovaSeq 6000 and the MGI DNBSEQ-T7. Both are established whole-genome sequencing platforms with published head-to-head evaluations. A practical comparison published in Life Science Alliance, which tested these instruments alongside PacBio and Oxford Nanopore systems using a yeast genome, found the two short-read platforms differ subtly in their error profiles: the NovaSeq 6000 exhibited higher frequency of single-base-pair insertions and deletions, whereas the DNBSEQ-T7 showed more indels longer than 8 base pairs.

In other words, Illumina data were advantageous for extending contigs but more vulnerable to single-base indel errors than the MGI data, the study found. For most applications these differences matter mainly to bioinformaticians, but they illustrate that "short read" is not a monolith—two leading platforms of the same generation produce measurably different variant calls.

Cost is where short reads shine. Complete Genomics, an MGI affiliate, publishes comparisons stating that its DNBSEQ-T7 delivers a $150-per-genome cost, versus roughly $200 per genome for Illumina's flagship NovaSeq X Plus instrument. These are manufacturer figures and institutional pricing varies, but the pattern is consistent: short-read sequencing remains the cheapest route to deep, accurate coverage of a genome.

Long-Read Sequencing: PacBio and Oxford Nanopore

PacBio's Sequel and Oxford Nanopore's instruments trade raw cost for reach. Because reads can span 25–30 kilobases, they cover repetitive and complex genomic regions that fragment short-read assemblies. A review of sequencing technologies reports that long reads excel at identifying complex structural variants—large insertions, deletions, inversions and duplications—and, thanks to PCR-free library preparation, at detecting DNA methylation directly.

Oxford Nanopore has been closing the throughput gap. Front Line Genomics reports that the company's PromethION system now supports up to 200 gigabases per flow cell with improved basecalling algorithms and adaptive sampling, "pushing it into the realm of population-scale genomics." The same outlet notes that long-read sequencing, once troubled by accuracy problems, is now a viable option for many clinical and research applications.

Accuracy has also improved through method design. A Federal Judicial Center reference document highlights peer-reviewed work demonstrating high-accuracy long-read amplicon sequencing using unique molecular identifiers with either nanopore or PacBio instruments, indicating that laboratories have established approaches to compensate for the platforms' native error profiles.

NGS Platform Comparison: Short-Read vs. Long-Read Technologies

The table below juxtaposes the two platform families across the dimensions that drive most purchasing and grant decisions. Read it as a decision boundary: move down the long-read column only when your experiment demands what short reads cannot physically deliver.

The comparison surfaces the primary boundary researchers face: short reads win on accuracy per dollar, long reads win on information no short read can capture. A clinical metagenomics platform guide cautions that cost per gigabase should be treated as only one metric—selection also depends on sample input, read yield, turnaround time, and whether the downstream analysis workflow is validated for the platform's read length and error profile.

Matching Technology to Research Application

Transcriptomics illustrates the short-read case. RNA-Seq, a widely used NGS application for profiling the complete set of RNA molecules, relies on high-throughput, cost-effective readouts of gene expression, alternative splicing and non-coding RNA regulation. Reviewing the technology's role, researchers note NGS offers exactly the depth and affordability such expression studies require, and short-read sequencing is specifically useful for determining sequence abundance, profiling transcript expression, and identifying variants.

Whole-genome sequencing of complex regions flips the calculus. When studying complex organisms with little reference data, long-read sequencing on a third-generation platform is probably the most appropriate option, Front Line Genomics advises. Long reads provide comprehensive genome coverage and resolve structural variants that short reads misassemble, and they capture methylation data without a separate assay.

Platform-specific quirks matter at the margins, too. The Life Science Alliance comparison found that assembly quality depended not just on the sequencer but on the assembler pairing, with Illumina-based datasets producing equal or higher assembly completeness under certain pipelines. Budget, reference availability, and bioinformatics capacity therefore belong in the decision alongside raw specifications—and no comparison of published cost estimates substitutes for your own institution's pricing, which varies significantly with consumables and scale.

Choosing Your NGS Platform: A Decision Framework

Researchers should select an NGS platform by first defining their primary research objective—high-accuracy SNP detection, structural variant resolution, de novo assembly, or methylation profiling—and then evaluating the trade-offs in read length, accuracy, and cost presented by short-read versus long-read technologies. Counting SNPs cheaply at scale points to Illumina or MGI; resolving an insertion, inversion or methylation state points to PacBio or Oxford Nanopore. The measurable indicator of a sound choice is the alignment of chosen platform's core strengths (e.g., short-read for high-throughput SNP calling, long-read for complex genome assembly) with the specific experimental design and expected genomic features. Before committing budget, request current institutional quotes and confirm your analysis pipeline is validated for the platform's read length and error profile.

Sources

• Next-Generation Sequencing Technology: Current Trends and Advancements - PMC
• A practical comparison of the next-generation sequencing platform and assemblers using yeast genome — Life Science Alliance
• Completegenomics
• DNA Sequencing: How to Choose the Right Technology - Front Line Genomics
• DNA Sequencing Technologies, How They Differ, and Why It Matters — FJC
• NGS Platform Comparison 2026 for Clinical mNGS — Micronbrane Medical